- Home
- ANIX vs ASMB Comparison
ANIX vs ASMB Comparison
Compare ANIX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ASMB
- Stock Information
- Founded
- ANIX 1982
- ASMB 2005
- Country
- ANIX United States
- ASMB United States
- Employees
- ANIX N/A
- ASMB N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- ASMB Health Care
- Exchange
- ANIX Nasdaq
- ASMB Nasdaq
- Market Cap
- ANIX 101.4M
- ASMB 110.8M
- IPO Year
- ANIX 1987
- ASMB 2010
- Fundamental
- Price
- ANIX $3.08
- ASMB $16.59
- Analyst Decision
- ANIX Strong Buy
- ASMB Buy
- Analyst Count
- ANIX 2
- ASMB 2
- Target Price
- ANIX $8.50
- ASMB $35.00
- AVG Volume (30 Days)
- ANIX 42.0K
- ASMB 34.3K
- Earning Date
- ANIX 10-29-2024
- ASMB 11-06-2024
- Dividend Yield
- ANIX N/A
- ASMB N/A
- EPS Growth
- ANIX N/A
- ASMB N/A
- EPS
- ANIX N/A
- ASMB N/A
- Revenue
- ANIX N/A
- ASMB $21,481,000.00
- Revenue This Year
- ANIX N/A
- ASMB $267.67
- Revenue Next Year
- ANIX N/A
- ASMB $46.15
- P/E Ratio
- ANIX N/A
- ASMB N/A
- Revenue Growth
- ANIX N/A
- ASMB N/A
- 52 Week Low
- ANIX $2.15
- ASMB $7.68
- 52 Week High
- ANIX $5.13
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- ANIX 41.08
- ASMB 50.37
- Support Level
- ANIX $2.95
- ASMB $17.27
- Resistance Level
- ANIX $3.11
- ASMB $18.98
- Average True Range (ATR)
- ANIX 0.12
- ASMB 1.20
- MACD
- ANIX -0.01
- ASMB 0.20
- Stochastic Oscillator
- ANIX 19.35
- ASMB 50.92
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.